Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer
Metrics: PDF 694 views | HTML 1239 views | ?
Fanming Kong1, Fangfang Gao2, Jun Chen1, Yiyu Sun1, Ying Zhang1, Honggen Liu1, Xiaojiang Li1, PeiYing Yang1, Rongxiu Zheng2, Geli Liu2 and Yingjie Jia1
1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
2 Department of Pediatrics, Tianjin Medical University General Hospital, Tianjin, China
Yingjie Jia, email:
Keywords: lung cancer, non-small-cell lung cancer, LAPTM4B-35, cancer recurrence, prognosis
Received: April 16, 2016 Accepted: June 13, 2016 Published: July 28, 2016
Background: The expression levels and clinical significances of Lysosomal-associated protein transmembrane-4β-35 (LAPTM4B-35) protein are unknown in the non-small-cell lung cancer (NSCLC). This study aimed to explore the expression and prognostic value of LAPTM4B-35 in NSCLC patients. Methods: The clinicopathological and survival data of 107 NSCLC patients who received radical surgery from 2007 and 2011 were reviewed. The LAPTM4B-35 expression of the paired tumors and adjacent normal specimens were detected, and the association between LAPTM4B-35 and clinical variables was explored. Kaplan-Meier analysis and Cox regression (Proportional hazard model) were performed to investigate the prognostic significance for NSCLC. Results: LAPTM4B-35 was over expressed in NSCLC tissues. The elevated LAPTM4B-35 expression was associated with cancer recurrence (P = 0.031). The 5-year median OS and PFS were significantly worse in the LAPTM4B-35 overexpressed group. Multivariate Cox analysis showed that LAPTM4B-35 over-expression was an independent factor for OS and PFS in NSCLC(P = 0.018, P = 0.026, respectively). Conclusions: The overexpressed LAPTM4B-35 was an independent prognostic biomarker for NSCLC, which could predict cancer recurrence and poor over survival. And that may be applied as potential target for NSCLC treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.